Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Meet the Author: prof. Brian Rini and prof. Toni Choueiri

In this e-learning, authors prof. Brian Rini and prof. Toni Choueiri. are queried by a panel of fellow oncologists about the recent results of the Keynote-426 and Javelin 101 Renal studies.  

In both phase III trials, the combination of an immunotherapy agent with the tyrosine kinase inhibitor axitinib was compared to sunitinib as first line treatment of advanced renal cell carcinoma. The panel of experts, led by prof. John Haanen, will thoroughly discuss the results of these trials with both authors. 

This program provides the opportunity to gain detailed knowledge of the Keynote-426 en Javelin 101 Renal trials. Together with the authors, the expert panel will offer profound insight into the setup and execution of both trials. They will discuss the different results and assess their impact on daily clinical practice.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ, Penkov K, Haanen J et al. N Engl J Med 2019; 380:1103-1115.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI, Plimack ER, Stus V, et al. N Engl J Med 2019; 380:1116-1127.

Authors

  • Prof. Brian Rini, MD - medical oncologist, Vanderbilt-Ingram Cancer Center, Nashville, US;
  • prof. Toni Choueiri, MD - medical oncologist, Dana-Farber Cancer Institute, Boston, US.

Discussion panel

  • Prof. John Haanen, MD, PhD - medical oncologist NKI-AvL, Amsterdam;
  • Axel Bex, MD, PhD - urologic surgeon, Royal Free Hospital, London, UK;
  • Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen.
  • Sponsors

    This program is editorially independent and is financially supported by:

Related items

Congress news 22/06/2020

ASCO Discussion Round II: Highlights from a European Perspective

In this second round table discussion, experts from Switzerland and Germany discuss practice-changing studies in the fields of Head & Neck Tumors and Lung Cancer with the ASCO2020 original authors.  The following authors are presenting their studies:  Prof. Dr. Kevin Joseph Harrington The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, United Kingdom KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).            Prof. Dr. Martin Reck LungenClinic Grosshansdorf, Grosshansdorf, Germany Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.   Prof. Dr. Joel Guigay                 Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, France TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).   John Kuruvilla, MD (Dr.) Princess Margaret Cancer Centre, Toronto, ON, Canada KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

ASCO Discussion Round III: Highlights from a European Perspective

In this third live discussion round, experts from Switzerland and Germany discuss practice-changing studies in the fields of GU, Immunoncology and Hematology with the ASCO2020 original authors.  The following authors are presenting their studies:  Dr. Thierry André Sorbonne University and Saint-Antoine Hospital, Paris, France Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study   Prof. Dr. Shaji Kumar Mayo Clinic, Rochester, MN, USA Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.   Dr. Landon Carter Brown Duke Cancer Institute, Durham, North Carolina, USA Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.   Dr. Jesus G. Berdeja Sarah Cannon Research Institute, Nashville, TN, USA Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.   Prof. Dr. Thomas Powles Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, UK Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

AML, MDS, MPN - Dr. Goede // Highlights EHA25

In this presentation, PD Dr. Goede from the Cantonal Hospital in Winterthur presents his Highlights for the topic " AML, MDS, MPN " from the EHA25 virtual Meeting. TOPICS AML LB2601: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A Courtney DiNardo et al.   S139: ENASIDENIB PLUS AZACITIDINE SIGNIFICANTLY IMPROVES COMPLETE REMISSION AND OVERALL RESPONSE RATES VERSUS AZACITIDINE MONOTHERAPY IN MUTANT-IDH2 NEWLY DIAGNOSED AML. Courtney DiNardo et al. S144: THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINDE WITH AZACITIDINE IS WELL TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS Naval Daver et al.   MDS S183: TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE IN HEAVILY TRANSFUSED NODN-DEL5Q LOWER RISK MDS RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS Uwe Platzbecker et al.,   MPN  S217: RUXOLITINIB DISCONTINUATION SYNDROME: INCIDENCE, RISK FACTORS AND MANAGEMENT IN 242 PATIENTS WITH MYELOFIBROSIS Francesca Palandri et al.

Congress news 22/06/2020

Aggressive Lymphoma – Professor Renner // Highlights EHA25

In this presentation, Prof. Renner from the Oncology Center in Zurich presents his Highlights for the topic "Aggressive Lymphoma (incl. Hodgkin + MCL)" from the EHA25 virtual Meeting. TOPICS S101: POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG Peter Borchmann LB2600: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PEMBROLIZUMAB (PEMBRO) VERSUS BRENTUXIMAB VEDOTIN (BV) FOR TREATMENT OF RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-204 Pier Luigi Zinzani S230: ROLE OF RADIOTHERAPY AND DOSE-DENSIFICATION OF R-CHOP IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A SUBGROUP ANALYSIS OF THE UNFOLDER TRIAL OF THE GERMAN LYMPHOMA ALLIANCE (GLA). Gerhard Held S235: OUTCOME OF LIMITED STAGE PERIPHERAL T-CELL LYMPHOMA AFTER CHOP(-LIKE) THERAPY: A POPULATION BASED STUDY OF 251 PATIENTS FROM THE NORDIC LYMPHOMA EPIDEMIOLOGY GROUP Ahmed Ludvigsen Al-Mashhadi S236: HIGH DOSE METHOTREXATE CNS PROPHYLAXIS IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A MULTICENTRE ANALYSIS OF TOXICITY AND IMPACT ON R-CHOP DELIVERY Matthew Wilson S243: OUTCOME OF HIGH-GRADE LYMPHOMA PATIENTS TREATED WITH CD19 CAR-T – UPDATED REAL-WORLD EXPERIENCE IN THE UK Andrea Kuhnl

Congress news 22/06/2020

European clinicians share their local perspectives on practice changing studies from EHA25 Virtual

MEDtalks in association with The European Hematology Association has launched a series of four webinars, covering some of the most important practice changing studies presented at EHA25 Virtual. We invited leading European clinicians and study authors from the UK, Germany, Spain, the Netherlands and Switzerland to discuss the relevance of these studies for their local clinical practice. The webinar series was divided into the following topics: Multiple Myeloma & CAR-T, Lymphoma, CLL and AML. You can watch the webinars below: Multiple myeloma & CAR-T Webinar Lymphomas Webinar CLL Webinar AML Webinar All webinars are moderated by PD Dr. med. Jens Ulrich Rüffer. The webinars are independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

Myeloma - Dr. Zander // Highlights EHA25

In this presentation, Dr. Zander from the Cantonal Hospital in Luzern presents his Highlights for the topic "Myeloma" from the EHA25 virtual Meeting. TOPICS NDMM: Best Triplet?             Endurance: Phase 3 VRd versus KRd NDMM: Triplet vs. Quadruplet?             High-Risk (HR) MM: SWOG1211 Trial: Phase VRd vs VRd + Elotuzumab             GMMG HD6 Trial: Phase 3 VRd vs VRd + Elotuzumab NDMM: Stamina Update: Duration of Maintenance; Tandem in HR MM   Relapsed MM:             Bispecific Antibody: Teclistamab CD3xBCMA             CART

Congress news 22/06/2020

CLL & Indolent Lymphoma - Prof. Rossi // Highlights EHA25

In this presentation, Prof. Rossi from the Oncology Institute in Southern Switzerland presents his Highlights for the topic "CLL & Indolent Lymphoma" from the EHA25 virtual Meeting. TOPICS S155: FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL Othman Al-Sawaf S158: FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT Tanya Siddiqi S156: EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL PHASE 3B TRIAL (VENICE I) Arnon Kater S159: ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ASCEND FINAL RESULTS Paolo Ghia S225: ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) Meletios Dimopoulos